- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Winter 2015
| Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
|---|---|---|---|---|---|
| Avodart | GlaxoSmithKline | Dutasteride Capsules | Teva | indicated for the treatment of the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate | 10/12/2015 |
| Lescol XL | Novartis | Fluvastatin Sodium Extended-Release Tablets | Sandoz | indicated as an adjunctive therapy with changes to diet to lower cholesterol, slow the progression of heart disease, and reduce the risk of needing procedures to improve blood flow to the heart | 10/16/2015 |
| PhosLo Gelcaps | Fresenius Medical Care North America | Calcium Acetate Capsules | Lupin Pharms | indicated for control of hyperphosphatemia in end stage of renal failure | 10/26/2015 |
| Fusilev | Spectrum Pharms | Levoleucovorin Calcium Injection | Mylan | indicated for rescue use after high-dose methotrexate therapy in osteosarcoma; also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists | 10/27/2015 |
| Glucotrol XL | Pfizer | Glipizide Extended-Release Tablets | Mylan | indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus | 11/16/2015 |
| Viramune XR | Boehringer Ingelheim | Nevirapine Extended-Release Tablets | Mylan | used in combination with other antiretroviral agents for treatment of HIV-1 infection in adults and in children 6 to less than 18 years of age | 11/16/2015 |
| Axert | Janssen Pharms | Almotriptan Tablets | Mylan | used for the acute treatment of migraine attacks in adult patients with history of migraine with or without aura | 11/17/2015 |
| Adderall | Teva | Dextroamphetamine Saccharate / Amphetamine Aspartate / Dextroamphetamine Sulfate / Amphetamine Sulfate Tablets (mixed salts of a single entity amphetamine product) | Mylan | indicated for the treatment of attention deficit hyperactivity disorder (ADHD) | 11/19/2015 |
| FazaClo ODT | Jazz Pharm | Clozapine Orally Disintegrating Tablets | Mylan | treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment | 11/24/2015 |
| Zyvox | Pfizer | Linezolid Tablets | Mylan | treatment of certain infections caused by susceptible Gram-positive bacteria | 12/29/2015 |
GENERICally Speaking Winter 2015
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.